AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$AUPH

TANG KEVIN purchased $12.5M of AUPH (indirect holdings)

TANG KEVIN (Chief Executive Officer) purchased 814,606 indirectly-held shares of Aurinia Pharmaceuticals Inc. (AUPH) at an average of $15.29 ($15.28–$15.35, $12.46M total) across 5 trades over 2026-05-29 to 2026-06-02. Filed jointly with TANG CAPITAL MANAGEMENT LLC (10% owner).

Original reporting
SEC EDGAR · TANG KEVIN, TANG CAPITAL MANAGEMENT LLC
Published Jun 3, 2026, 1:54 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:46 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$AUPH
Bullish
high confidence
Mentioned
$AUPH
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AUPHBullishMed
01

Why it matters

The purchase adds to the CEO's ownership, suggesting confidence and may influence short‑term price dynamics.

02

Market read

First‑report insider buy of $12.5M could prompt short‑term buying interest in AUPH.

03

What to watch

Potential upcoming clinical data releases that could be driving the purchase.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$AUPHBullishHigh confidence
Context

CEO Kevin Tang bought 814,606 shares for $12.5M, increasing his stake to over 13M shares.

Expected impact

likely upward pressure as market prices in the insider buy.

Evidence & confidence

Form 4 filing is a primary source; the $12.5M purchase by the CEO is material for a micro‑cap biotech.

Market effects

Sector

May lift sentiment in the biotech sector as insider confidence is viewed positively.

Regional

Limited to US markets where AUPH trades.

Global

Minimal global impact beyond niche biotech investors.

Counterpoint

What could challenge this read

Insider buying could be a window‑dressing move; fundamentals remain uncertain.

Key entities

  • person
    Kevin Tang

    Chief Executive Officer of Aurinia Pharmaceuticals

  • company
    Aurinia Pharmaceuticals Inc.

    Biotech firm listed on Nasdaq under ticker AUPH

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AUPH insider trading history →

Related articles

$AUPHMedAI 8/10

Aurinia Skids on Results

Aurinia Pharmaceuticals reported Q3 and YTD 2026 revenue of $83.7M and $244.6M, up 14% and 19% YoY. LUPKYNIS sales rose 12% and 18% YoY for the same periods. License, collaboration, and royalty revenue increased 54% and 39% YoY. Net income before taxes grew 21% and 67% YoY.

baystreet.ca
$AUPHHigh

Aurinia Pharmaceuticals stock falls 3% on Q3 miss, soft guidance

Aurinia Pharmaceuticals (AUPH) reported Q3 earnings of $0.23 per share, missing estimates by $0.01, and revenue of $83.7M, slightly below expectations. Shares fell 3.43% premarket. The company raised 2026 revenue guidance to $325M-$330M, below analyst consensus. LUPKYNIS sales grew 12% YoY to $79.4M. The company also initiated a Phase 4 study for lupus nephritis treatments.

investing.com
$AUPHHigh

Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress

Aurinia Pharmaceuticals Inc. (AUPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress EDMONTON, Alberta – October 30, 2026 – Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial resul

SEC EDGAR 8-K